Arginine Cuts Alzheimer's Plaques in Mice, Improving Memory as Low-Cost Oral Option Emerges
Updated
Updated · Earth.com · May 9
Arginine Cuts Alzheimer's Plaques in Mice, Improving Memory as Low-Cost Oral Option Emerges
2 articles · Updated · Earth.com · May 9
AppNL-G-F mice given arginine in drinking water for weeks developed fewer amyloid plaques, lower insoluble Aβ42 levels and better performance on memory and behavior tests; treated fruit flies also lived longer.
Dose-dependent lab experiments showed arginine slowed aggregation of sticky Aβ42, supporting the idea that the amino acid acts as a chemical chaperone that helps prevent toxic protein clumping.
Brain inflammation also eased in treated mice, with lower activity in genes linked to microglia-driven inflammatory signaling — a second disease pathway moving in the same direction as plaque reduction.
Arginine is already sold cheaply, crosses the blood-brain barrier and has an established human safety record, potentially making it faster and far less costly to test than IV antibody therapies.
The findings, published in Neurochemistry International, come from fly and familial-Alzheimer's mouse models, so researchers still need human trials and dose calibration before judging relevance to common Alzheimer's cases.
Could a cheap amino acid really outperform the multi-billion dollar drugs developed for Alzheimer's treatment?
If high arginine is neurotoxic, how could this common amino acid safely be used to treat Alzheimer's disease?
Arginine as a Low-Cost, Safe Candidate for Alzheimer’s: Promising Results in Animal Models and the Road to Human Trials
Overview
Recent research highlights arginine as a promising candidate for Alzheimer's disease treatment, especially in animal models. By using a drug repositioning strategy, scientists are exploring new uses for existing safe compounds like arginine, which is already approved for clinical use in Japan and can effectively enter the brain. This approach helps bypass many early challenges in drug development. Notably, studies show that oral arginine can suppress amyloid-beta pathology, a key feature of Alzheimer's. These findings suggest that arginine could offer a practical and accessible path toward new therapies for Alzheimer's disease.